CRN01941 / Crinetics - LARVOL DELTA

A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=57; Completed; Sponsor: Crinetics Pharmaceuticals Inc.; Recruiting ➔ Completed; N=119 ➔ 57

Clinical • Enrollment change • Trial completion

Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors (GlobeNewswire, Crinetics Pharmaceuticals, Inc.) - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN01941 in healthy volunteers. CRN01941 is an oral nonpeptide somatostatin receptor subtype 2 (sst2) biased agonist designed for the treatment of neuroendocrine tumors (NETs) that originate from neuroendocrine cells commonly found in the gut, lung, or pancreas.

Clinical • New trial

A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=119; Recruiting; Sponsor: Crinetics Pharmaceuticals Inc.; Not yet recruiting ➔ Recruiting

Enrollment open